iBio, Inc. appointed Dr. Martin Brenner as new CEO

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 20, 2023, the Board of Directors (the "Board") of iBio, Inc., a Delaware corporation (the "Company"), appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately, and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023. The Company is continuing its search for a successor Chief Executive Officer and as such, Dr. Brenner's position of Interim Chief Executive Officer will end when the Company appoints a successor.



Dr. Brenner, age 52, has served as the Company's Chief Scientific Officer since January 18, 2021. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc.("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, Chief Scientific Officer of Pfenex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as Chief Scientific Officer at Recursion Pharmaceuticals, Inc., a biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig-Maximilians-University in Munich, Germany.



Mr. Duran, age 43, has served as the Company's Vice President of Financial Planning and Analysis (FP&A) since April 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, which is the 3rd largest generic pharmaceutical company in the United States, from May 2016 to May 2021. Prior to joining Lupin Pharmaceuticals, he held numerous strategy positions at Teva Pharmaceuticals in both its growth markets and Latin America offices. Mr. Duran also worked as a Manager, FP&A for both Bupa and Noven Pharmaceuticals. Mr. Duran holds a B.A. in Finance and an M.B.A from the University of Miami.



On December 23, 2020, the Company entered into an employment agreement with Dr. Martin Brenner to serve as the Company's Chief Scientific Officer, effective as of January 18, 2021. In addition to a base salary of $405,000 for serving as the Company's Chief Scientific Officer and a discretionary incentive bonus with a target of 40% of his annual base salary, while serving as Interim Chief Executive Officer, Dr. Brenner will receive a monthly cash stipend of $7,500. Dr. Brenner was also granted restricted stock units ("RSUs") to acquire 130,000 shares of the Company's common stock, $0.001 par value per share (the "Common Stock"), which RSUs shall vest pro rata over a twelve- month period, such vesting to terminate if Dr. Brenner is no longer the Company's Interim Chief Executive Officer. The grant-date fair value of the RSUs totaled approximately $91,000. On November 11, 2022, Dr. Brenner also received a RSU grant of 95,348 shares of Common Stock in exchange for Dr. Brenner's agreement to continue employment with the Company through July 1, 2023, whereby such RSUs will vest on the earlier of (i) July 1, 2023, or (ii) the successful achievement of the Company's 2023 objectives, as defined by the Board of Directors. 



On January 23, 2023, Mr. Duran accepted an offer letter from the Company for the Interim Chief Financial Officer (the "Offer Letter"). Pursuant to the terms of the Offer Letter, Mr. Duran will serve as the Company's Interim Chief Financial Officer, effective as of February 13, 2022. Upon his appointment to the position of Interim Chief Financial Officer, Mr. Duran's base salary will be increased from $300,000 to a base salary of $350,000, he will be eligible for a discretionary incentive bonus with a target of 40% of his annual base salary and he will be granted a $140,000 special incentive bonus (40% of his fiscal year 2023 annualized salary) in exchange for his agreement to continue employment with the Company through the earlier of: (a) July 1, 2023, or (b) the successful achievement of the Company's 2023 objectives, as defined by the Board of Directors minus any retention bonus he is paid during the fiscal year 2023. Before his appointment as the Company's Interim Chief Financial Officer, Mr. Duran became eligible to receive a retention bonus of $70,000 in exchange for Mr. Duran's agreement to continue employment with the Company through March 31, 2023.



Each of Dr. Brenner's and Mr. Duran's employment is on an "at will" basis and may be terminated at any time by either of them or the Company. If either Dr. Brenner or Mr. Duran separate from employment for any reason or no reason, they are entitled to receive their accrued and unpaid base salary, any unreimbursed expenses and benefits accrued through the 


termination date. If the Company terminates their employment for reasons other than for "Cause" (as defined in their respective employment agreements), the Company is required to pay the accrued and unpaid base salary, any unreimbursed expenses and benefits accrued through the termination/separation date and provided, that the terminated employee executes and does not revoke a separation agreement in form acceptable to the Company, he will receive (1) an amount equal to his base salary for nine months, (2) a pro rata share of any bonus earned by him during the Company's fiscal year in which he was terminated, within thirty (30) days of his execution of a separation agreement, and (3) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of nine (9) months following the termination.



If Dr. Brenner's or Mr. Duran's employment is terminated without Cause within twelve (12) months after a Change of Control (as defined in the Company's equity incentive plan), (or in the case of Dr. Brenner, Dr. Brenner terminates his employment with us for "good reason", as defined in his employment agreement), provided they execute and do not revoke a separation agreement in a form acceptable to the Company, they each will be entitled to receive: (1) an amount equal to his base salary for twelve months, (2) an amount equal to the target bonus for which he would have been eligible during the Company's fiscal year in which he was terminated, within thirty (30) days of his execution of a separation agreement, (3) immediate vesting of 100% of any unvested time-vested equity awards held by him at such time, and (4) payment of the full amount of all premiums for continued health benefits (including COBRA) under the Company's health plans for a period of twelve (12) months following the termination.



Dr. Brenner and Mr. Duran each has agreed to assign to the Company all of his rights in any Inventions, including all Intellectual Property Rights (as such terms are defined in the employment agreements) that are made, conceived or reduced to practice, in whole or in part, alone or with others, by him during his employment with the Company and have agreed to certain non-compete and non-solicitation terms.



There are no family relationships between Dr. Brenner and Mr. Duran and any of the Company's directors or executive officers. In addition, except as set forth above, neither Dr. Brenner nor Mr. Duran is a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.



The descriptions of the Brenner Employment Agreement and Duran Offer Letter do not purport to be complete and are qualified in its entirety by reference to the Brenner Employment Agreement and Duran Offer Letter, copies of which are filed as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K and are incorporated herein by reference.